SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Down 35.3% in December

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a large drop in short interest in December. As of December 31st, there was short interest totalling 36,500 shares, a drop of 35.3% from the December 15th total of 56,400 shares. Based on an average daily volume of 98,100 shares, the short-interest ratio is currently 0.4 days. Currently, 0.5% of the shares of the stock are sold short.

SAB Biotherapeutics Stock Down 4.7 %

Shares of SABS opened at $3.66 on Tuesday. SAB Biotherapeutics has a one year low of $2.16 and a one year high of $6.30. The company has a 50-day moving average of $3.60 and a two-hundred day moving average of $3.08. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%. As a group, equities analysts anticipate that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

An institutional investor recently bought a new position in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC bought a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned 0.21% of SAB Biotherapeutics at the end of the most recent reporting period. Institutional investors own 7.82% of the company’s stock.

Analyst Upgrades and Downgrades

SABS has been the topic of a number of research reports. Chardan Capital reiterated a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a report on Thursday, November 7th. Craig Hallum started coverage on SAB Biotherapeutics in a report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.40.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.